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Abstract
Breast cancer is a heterogeneous disease, and different subtypes of breast cancer show
distinct cellular morphology, gene expression, metabolism, motility, proliferation, and meta-
static potential. Understanding the molecular features responsible for this heterogeneity is
important for correct diagnosis and better treatment strategies. Extracellular vesicles (EVs)
and their associated molecules have gained much attention as players in intercellular com-
munication, ability to precondition specific organs for metastatic invasion, and for their
potential role as circulating cancer biomarkers. EVs are released from the cells and contain
proteins, DNA, and long and small RNA species. Here we show by high-throughput small
RNA-sequencing that EVs from nine different breast cancer cell lines share common char-
acteristics in terms of small RNA content that are distinct from their originating cells. Most
strikingly, a highly abundant small RNAmolecule derived from the nuclear 28S rRNA is
vastly enriched in EVs. The miRNA profiles in EVs correlate with the cellular miRNA expres-
sion pattern, but with a few exceptions that includes miR-21. This cancer-associated
miRNA is retained in breast cancer cell lines. Finally, we report that EVs from breast cancer
cell lines cluster together based on their small RNA signature when compared to EVs
derived from other cancer cell lines. Altogether, our data demonstrate that breast cancer
cell lines manifest a specific small RNA signature in their released EVs. This opens up for
further evaluation of EVs as breast cancer biomarkers.
Introduction
Breast cancer is the most common invasive cancer in women and the leading cause of cancer
deaths in females [1]. Importantly, detection of the disease at an early stage significantly
increases the 5-year survival rate [2,3]. Therefore, it is of great interest to develop molecular
and cellular diagnostic assays with potential to aid early diagnosis, clinical decision-making,
and patient management [4].
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In the last few years several studies have demonstrated that cancer cells produce and release
increased numbers of membranous vesicles into the extracellular environment compared to
normal cells [5,6,7,8]. These cancer-derived extracellular vesicles (EVs) carry proteins, DNA,
and RNA species from the originating cell [9,10,11,12] and act as mediators of intercellular
communication that may influence on the progression of the disease [13,14]. EVs from both
cancer cells and associated stromal cells play an important role in altering the tumor environ-
ment and may promote tumor cell migration, invasion, and formation of distant metastatic
niches [15,16,17,18,19]. EVs have also been demonstrated to play a role in cancer cell immune
evasion, suppression of apoptosis, and in the development of drug resistance [20,21,22,23].
Since EVs are detected in all body fluids, including blood, they are increasingly recognized as
potential sources for cancer biomarkers [24].
Cancer-derived EVs are in general heterogeneous, but can be divided into two main classes
based on their mode of biogenesis and size [25]. These are the exosomes of 30–120 nm that
derive from exocytosed multivesicular bodies [26,27,28], and ectosomes that are microvesicles
of 120–1000 nm shed from the plasma membrane [29,30]. Numerous reports have shown that
EVs derived directly from tumor cells, or from the extracellular fluids of cancer patients, have a
distinct molecular signature of proteins [31,32,33], mRNAs [34], and non-coding RNAs [6,35].
In particular, EV-associated micro RNAs (miRNAs) have gained much attention as signaling
substances in intercellular communication [36,37,38]. MiRNAs are small non-coding RNAs of
approximately 22 nucleotides (nt), which regulate the expression of target genes at the post-
transcriptional level. They play key roles in cellular processes like proliferation, differentiation,
and survival and are interesting candidates as cancer biomarkers [39,40,41,42]. MiRNA profil-
ing now appears as an important approach in the molecular characterization of tumor subtyp-
ing [43], disease progression [44], treatment strategy, and survival [45,46]. Small RNA deep-
sequencing have revealed that the cells contain a variety of other small RNA species, and some
of them are incorporated into and released in EVs [47,48,49,50]. How RNA species are selected
and sorted into EVs have not been identified, but different covalent modifications of miRNAs
have been noted that either prevent miRNAs from being incorporated in EVs, or facilitate the
incorporation [51]. The functional role of EV-associated small RNAs in cancer progression is
still largely unknown.
Here, we use high-throughput sequencing to determine the complete small RNA content in
EVs derived from nine breast cancer cell lines. By employing this comprehensive strategy, we
have identified common signatures in the breast cancer cell line-derived EVs that are distinct
from the intracellular small RNA expression pattern in the originating cells. This difference is
mainly due to high contents of non-miRNA small RNAs in EVs, especially a highly abundant
small RNA derived from the 28S rRNA. We find, with some exceptions, that the intracellular
miRNA expression pattern is mostly reflected in the EVs. Interestingly, the oncogenic miRNA
miR-21, which expression is highly associated with breast cancer, is retained in the breast can-
cer cell lines. This finding supports selectivity in the sorting and secretion of certain miRNA
species. Finally, small RNA signatures show that EVs from breast cancer cell lines cluster
together, and can be separated from EVs derived from other cancer cell types. This is an impor-
tant observation that support that small RNAs within cancer-derived EVs may be suitable as
breast cancer-specific biomarkers.
Methods
Cell culture
Human cancer cell lines MA-11, MDA-MB-231 (ATCC #HTB-26™), Hs578T (ATCC #HTB-
126™), AU565 (ATCC #CRL-2351™), HCC1428 (ATCC #CRL-2327™), MCF7 (ATCC #HTB-
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22™), HCC1187 (ATCC #CRL-2322™), DU4475 (ATCC #HTB-123™), HCC1569 (ATCC
#CRL-2330™), DLD1 (ATCC #CCL-221™), HPAF-II (ATCC #CRL-1997™) and LNCaP (ATCC
#CRL-1740™), were maintained at 37°C in 5% CO2 and cultured in either Dulbecco´s Modified
Eagle's Medium (DMEM) or Roswell Park Memorial Institute Medium (RPMI) supplemented
with 10% FBS.
All cancer cell lines, except MA-11, were obtained from the American Type Culture Collec-
tion (ATCC; www.atcc.org). The human MA-11 breast carcinoma cell line, established from
bone marrow micrometastases of a patient with breast cancer [52], was obtained by Øystein
Fodstad (Norwegian Radium Hospital, Oslo, Norway). Cell pellets and conditioned media
from the Melmet 1 (MM1) and Melmet 5 (MM5) melanoma cell lines were a gift from Dr. Siri
Tveito at the Norwegian Radium Hospital, Oslo, Norway, and were established from the biop-
sies of metastatic melanoma patients at the department of Tumor Biology, The Norwegian
Radium Hospital Oslo, Norway [53].
Extracellular vesicles isolation
EVs were isolated from cell culture media using the Total Exosome Isolation reagent according
to the protocol (Invitrogen/Life Technologies), publication number MAN000694. Conditioned
media was prepared from approximately 1×107 cells grown at 70% confluency in T175 cell cul-
ture flasks. Cell cultures were washed two times using PBS followed by 72 hours incubation
with 15 mL exosome-depleted medium at 37°C and 10% CO2. Exosome-depleted medium was
obtained by subjecting the FBS to ultracentrifugation, 120,000 g for 12 hours, before adding it
(10%) to DMEM or RPMI. Conditioned media was harvested and centrifuged for 30 min at
2,000 g and 4°C to remove detached cells and cell debris. The supernatant was transferred to a
new tube and 7.5 ml of Total Exosome Isolation reagent was added and the mixture was incu-
bated over night at 2°C. After incubation, the samples were centrifuged for 1h at 10,000 g. The
supernatant was discarded and the pellets consisting of extracellular vesicles were resuspended
in 200 μl PBS.
Vesicle size determination
The vesicle size distributions were measured by photon correlation spectroscopy using a Sub-
micron Particle-sizer (Model 360, Nicomp, Santa Barbara, CA, USA). To avoid possible inter-
ference caused by dust particles, test tubes were pre-rinsed with distilled water and bath-
sonicated for 10 min. In addition, all sample preparations were performed in a laminar airflow
bench. The vesicle samples were diluted with filtered (0.2 μmMilipore filters) distilled water to
provide appropriate count intensity (approx. 250–350 kHz) and measured in three parallels
(run time 10 min at 23°C). Both Gaussian and Nicomp algorithms were fitted to the experi-
mental data to find the distribution that best describes the vesicle population. As the fit error
was found to be smaller than 1.5, and the residual error was smaller than 10, Nicomp distribu-
tion was selected. The volume-weighted distribution was used to determine the mean diameter
and polydispersity index (PI) of all samples.
Immunoblotting
Cells and isolated EVs were lysed in RIPA buffer (100mM Tris-HCl pH8, 300 mMNaCl, 2%
NP-40, 1% sodium deoxycholate, 0.1% SDS) supplemented with Complete Ultra Mini EDTA-
free protease inhibitor mixture (1 tablet/10 ml, Roche Applied Science) and HaltTM phospha-
tase inhibitor cocktail (Thermo Fisher Scientific). 30 μg protein extracts were resolved on a
SDS-PAGE gel, transferred to a nitrocellulose membrane, and probed with antibodies recog-
nizing CD63 (sc-5275, Santa Cruz Biotechnology; 0.4 μg/ml) or actin (clone C4, MAB1501,
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Millipore; 1:500). The blots were developed using IRDye800CW-conjugated goat anti-mouse
secondary antibody (926–32210, LI-COR; 1:7000) and the Odyssey IR Imaging system.
RNA isolation and analysis
Small RNA from EVs was isolated using the Total Exosome RNA and Protein isolation Kit
according to the protocol, including “Enriching for Small RNAs” step (Invitrogen/Life Tech-
nologies), publication number MAN0006962.
Total RNA from the cultured cells was isolated using the TRIzol reagent (Invitrogen/ Life
Technologies) and enriched for small RNAs using the PureLink™miRNA Isolation Kit (Invi-
trogen/Life Technologies).
RNA quality and concentration were assessed with the Agilent 2100 Bioanalyzer (Thermo
Scientific). Total RNA and RNA after small RNA enrichment was analyzed using RNA 6000
Nano Kit (Agilent) and Small RNA Kit (Agilent), respectively.
Small RNA-Sequencing, SOLiD4/SOLiD 5500xl
20 ng of EV RNA and 120 ng cell RNA, both enriched for small RNA, was used as the starting
input for RNA-Seq library preparation. The preparation of the cDNA library was done accord-
ing to the protocol from Applied Biosystems SOLiD™ small RNA library preparation from Invi-
trogen. The cDNA fragments were barcoded in the PCR amplification step to enable
simultaneous sequencing of different samples in a single run. The cDNAs underwent 18 cycles
of PCR using barcoded primers. The PCR products were purified using PureLink™ PCR Micro
Kit (Invitrogen) and analyzed for size and concentration on Agilent 2100 Bioanalyzer using
DNA HS chips. Equal molar amount of each barcoded sample were pooled together in one
library, which subsequently were used in emulsion PCR to a total concentration of 0.5 pM.
Approximately 1 billion enriched beads were deposited on a full glass slide for SOLiD 5500xl
sequencing. Cell RNA from Hs578T and AU565 was previously sequenced on SOLiD4 [42],
SRA accession SRX273660 (AU565) and SRX273750 (Hs578T). All sequencing was performed
at the genomic facility, Nord University. Raw sequences were submitted to the National Center
for Biotechnology Information (NCBI) Short Read Archive, Bioproject PRJNA309295
Bioinformatics analysis
All bioinformatics analysis was performed with the CLC Genomics workbench 7.0. Raw reads
were first subjected to color space adaptor trimming. Further, reads above 29 nt and below 15
nt were discarded and tags with less than 10 copies were removed. All samples were normalized
by linear total count scaling, and tags with expression below 100 reads per million (RPM) in all
samples were removed.
For mapping, the human genome with annotation was downloaded from the Ensembl
genome database (GRCh37.74) [54]. Mapping was performed by the use of the RNA-Seq Anal-
ysis Tool in the CLC Genomics workbench, with the settings Mapping type = Also map to
inter-genic regions, Color space alignment = Yes, Length fraction = 1.0, Similarity fraction = 0.9,
and Strand specific = Forward.
Hierarchal clustering analyses were performed with custom setting for CLC Genomics
workbench (Euclidean distance, single linkage, Log2 transformed expression values).
Micro RNA validation assays
0.2 ng (per replicate) of small RNA enriched RNA were used for small RNA expression quanti-
fication using the miRCURY LNA™ Universal RT PCR system (Exiqon, Denmark) according
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to the manufacturer recommendations. All experiments were done in triplicates, and a no tem-
plate control (H2O) was included for each primer set. The LightCycler1 96 was used for quan-
tification, and the ΔΔCq-method was used to calculate fold change using miR-23 as internal
reference. MiR-23 was validated as an internal reference by a bioinformatic approach using the
SOLiD small RNA-Seq data. Here, small RNAs with a p-value (EV versus cell line) higher than
0.9 and expression above 1000 read per million (RPM) in both EV and cell lines were filtered
for. This resulted in a list of seven small RNAs. MiR-23 was selected as it had the lowest stan-
dard deviation out of the miRNAs with a miRNA specific sequence identity.
Results
The small RNA content in breast cancer cell line-derived extracellular
vesicles is distinct from their originating cells
Cancer cells produce and release high numbers of EVs that contain a variety of biomolecules
including proteins, DNA, and RNA. However, it is still debated if the secreted cargo simply
reflects the intracellular content of the originating cell, or if the process is selective, allowing
only certain molecules to be sorted into vesicles destined for secretion. To get a comprehensive
picture of small RNA species secreted by breast cancer cells, we isolated EVs from the growth
media of nine breast cancer cell lines. The cell lines were selected based on their classification
as luminal (MCF7, HCC1428, and AU568), Basal B (Hs578T, MDA-MB-231, and MA-11), or
Basal A (HCC1569, DU4475 and HCC1187), assumed to reflect the most common subtypes,
and the heterogeneity of breast cancer. Although breast tumours are classified in six subtypes
(Luminal A, Luminal B, ERBB2/HER2+, Basal-like, Claudin-low and Normal breast-like), only
three different subtypes of cancer cell lines are identified based on gene expression; Luminal,
Basal A and Basal B. Even though a significant discrepancy of subtypes between primary
tumours and cell lines exist, comparison have shown that cell lines mirror both the genomic
heterogeneity and the recurrent genome copy number abnormalities found in primary
tumours. The sizes of isolated EVs ranged from 17 to 438 nm, with some variations in the rela-
tive distribution pattern among the different cell lines (data not shown). Western blot analyses
confirmed that the isolated EVs from Hs578T were enriched for the tetraspanin CD63, a well-
known exosomal marker protein (S1 Fig). We generated small RNA libraries from both EV
and cellular fractions and sequenced them on either the SOLiD4 or SOLiD 5500xl platform
(Fig 1).
Following adaptor trimming, size selection, and sampling count, 48,824,105 cellular reads
and 23,131,082 EV-derived reads mapped to the human genome (GRCh37.74). Of note,
whereas 57% of the reads derived from EV RNAmapped to only a single location in the
genome (unique mapping), only 37% of cellular reads mapped uniquely. However, as small
RNAs transcribed and processed from non-unique genomic loci might be as important as
those deriving from unique loci in terms of both biological functions and cancer biomarkers,
no filter was used to exclude sequences based on their mapping position. This generated a list
of 222,932 tags (unique sequencing reads) for the breast cancer cell lines and their correspond-
ing EVs. For differential expression analysis and further comparison studies, only tags with
expression higher than 100 reads per million (RPM) in at least one sample were included. This
resulted in a total of 6,375 tags (Fig 1; S1 Table). The sequencing data was validated by RT-
qPCR (S2 Fig).
To compare the small RNA transcriptome of EVs and cells, we performed hierarchical clus-
ter analysis (Fig 2). Based on small RNA expression, neither the breast cancer cell lines nor
their corresponding EVs clustered according to their subtypes (Basal A, Basal B, or Luminal).
In contrast, the intracellular small RNA content in the different breast cancer cell lines
smallRNA Signatures in Extracellular Vesicles from Breast Cancer
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Fig 1. Data analysis pipeline for reads generated from small RNA SOLiD sequencing in the breast cancer
cell lines and their corresponding EVs.
doi:10.1371/journal.pone.0161824.g001
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correlated more to each other, than to the small RNA content of their corresponding EVs.
The small RNA content in EVs derived from three of the cell lines, MA11, HCC1428, and
HCC1187, differed substantially from that of the cell lines and the rest of the EVs. This indi-
cates that these cell lines might share common features in the sorting of small RNA species for
secretion that are distinct from the other cell lines.
The majority of small RNAs in extracellular vesicles are not micro RNAs
As hierarchical cluster analyses clearly indicated that the small RNA content in EVs and cells
differed substantially, we further investigated the origin of the small RNA species from both
compartments. Approximately one third of the reads generated from the cell (27%) and EV
Fig 2. Hierarchical clustering of breast cancer cell lines and corresponding EVs on the basis of expression
of 6375 unique small RNAs.
doi:10.1371/journal.pone.0161824.g002
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(30%) fractions mapped to loci encoding miRNAs (Fig 3A). However, the reads were divided
among a higher number of distinct miRNA species in the cellular fraction. Interestingly, EVs
from the cell lines MA11, HCC1428 and HCC1187 contained fewer miRNAs species in relation
to total small RNA species compared to the other EVs (Table 1). As this is not reflected in their
cellular miRNA expression patterns, these cell lines appear to retain many of their miRNAs.
Strikingly, a large majority of EV-derived small RNA reads (43%) mapped to rRNA (Fig 3A).
In contrast, only 1% of cellular reads mapped to rRNA.
To gain more insight into what makes EVs unique in their small RNA content, we examined
the twenty most abundant small RNA species in the EVs (Fig 3B). Interestingly, thirteen of the
most abundant small RNAs in EVs were non-miRNAs, and seven of these derived from the
28S rRNA (srRNA). Furthermore, six of these srRNAs started at the exact same position corre-
sponding to the 5’ end of the 28S rRNA gene, but slightly differed in length (Fig 3C). RT-qPCR
analyses verified a high abundance of the 19 nt 5’ srRNA in EVs compared to the cells (S3 Fig).
We also examined the twenty most highly expressed small RNAs in the cell lines (Fig 3D). In
contrast to the EVs, seventeen of the most abundant cellular small RNAs were miRNAs. Taken
together, our analyses on the nine cell lines clearly show that the overall small RNA composi-
tion in EVs is distinct from the intracellular expression pattern.
The cellular micro RNA expression profile is partially reflected in the
extracellular vesicles
We then went on to analyze the correlation between all EV-derived and cellular small RNA spe-
cies in each individual cell line. The cells divided into two groups based on the correlation; those
that displayed moderate correlation, and those that displayed weak correlation (Fig 4). Not sur-
prisingly, the cell lines with weak correlation are the three cell lines that clustered separately
based on their EV-derived small RNA content. To study if the miRNA content in the EVs reflects
the cellular miRNA expression pattern, we plotted the miRNA read counts against each other
(colored red in the scatter plot) (Fig 4). Interestingly, all cell lines displayed linear correlations
between EV and cellular miRNAs. Of note, this was also the case for the HCC1428, HCC1187,
andMA11 cell lines even though the abundance of miRNAs was significantly higher in the cells
compared to the EVs. Calculation of Pearson’s correlation coefficients confirmed a high correla-
tion between EV-derived and cellular miRNA in all cell lines (p = 0.671 ± 0.053) (Table 2). In
contrast, the correlation between EV-derived and cellular non-miRNA small RNAs was very low
(p = 0.082 ± 0.221). This clearly demonstrates that whereas the cellular miRNA content is
reflected in the EVs of each cell line, the composition of other small RNA species differ substan-
tially in EVs and their corresponding originating cell line.
We observed that some miRNAs were retained in the cells, including miR-21-5p and miR-
29b-3p (Fig 3D). Fifty different isoforms (isomiRs) of miR-21-5p were detected in the breast
cancer cell lines (data not shown), and two isoforms including the mature sequence, were
among the most highly expressed cellular miRNAs. RT-qPCR analyses confirmed higher levels
of miR-21-5p in cellular compared to EV fractions (S4 Fig).
Extracellular vesicles from breast cancer cell lines are distinct from other
cancer cell lines
To explore if the small RNA signatures of the EVs from the breast cancer cell lines are unique
from other cancer EVs, we deep-sequenced the small RNA content of EVs derived from five
non-breast cancer cell lines. These include LNCaP (prostate cancer), DLD1 (colorectal cancer),
HPAF-II, (pancreas cancer) and two melanoma-derived cell lines (MM1and MM5). A total of
29,037,189 filtered reads were generated representing 191,210 unique small RNA sequences.
smallRNA Signatures in Extracellular Vesicles from Breast Cancer
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Fig 3. The group of non-miRNA small RNA species distinguished the EVs from their parental cell lines. A)
Transcriptome subtype distribution of small RNA sequence reads combined for the nine breast cancer cell lines
and for the nine breast cancer EVs. B) The expression level of the 20 most abundant small RNAs in the EVs is
smallRNA Signatures in Extracellular Vesicles from Breast Cancer
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Mapping of the sequencing reads to the human genome showed that 28% of the small RNA
reads mapped to genes encoding miRNAs, which is similar to what was observed for the breast
cancer cell lines (Fig 5A). However, only 9% of the reads mapped to rRNA genes, which is
strongly opposed to the data from the breast cancer cell lines where 43% of the small RNAs
derived from rRNA. Despite of this, the non-breast cancer cell lines secreted equal amounts of
the 28S rRNA-derived srRNA (5’-19 nt) as the breast cancer cell lines (Fig 5B). We then com-
bined the new sequencing tags with tags derived from the EVs of the breast cancer cell lines,
using an expression cut off value of>100 RPM for at least one sample. This resulted in a list of
6,569 tags (S2 Table) that were subjected to hierarchical cluster analyses (Fig 5C). Based on the
total small RNA content in the EVs, the MA11, HCC1428, and HCC1187 still formed a distinct
cluster that differed from both the other breast cancer cell lines and the non-breast cancer cell
lines. The rest of the breast cancer cell lines and the two melanoma cell lines formed separate
clusters, indicating that the small RNA content within the EVs reflects the origin of the cancer.
Interestingly, this was even more pronounced when hierarchal clustering was done based on
only the miRNA composition in the EVs (Fig 5D). Here, eight of the nine breast cancer cell
lines clustered together. This implies that the EV-derived miRNAs from the breast cancer cell
lines form a unique signature that distinguishes them from EVs derived from other cancer
types.
Discussion
High throughput sequencing has during the last few years broadened the concept of small reg-
ulatory RNAs, and novel classes have been discovered with potential biological functions.
There are several reports that miRNAs and other small RNA species are incorporated into cell-
secreted vesicles, and it is now generally accepted that EVs can act as mediators of intercellular
communication [12,34,55,56,57,58,59,60]. Such communication has recently been shown to
play key roles in cancer progression [34,61,62,63,64,65,66]. As EVs can be detected in body flu-
ids, their molecular content holds great premises as cancer biomarkers. Here, we find by small
RNA deep sequencing that EVs derived from nine different breast cancer cell lines have a dis-
tinct composition of small RNA species compared to their originating cells. This is mostly con-
ferred by EV-specific presence of high amounts of rRNA-derived small RNAs (srRNAs).
Furthermore, we find that the miRNA content in the EVs largely reflects the intracellular
miRNA expression pattern, but there are some interesting exceptions. Importantly, by compar-
ing miRNA patterns in EVs derived from different cancer cell lines, we find that the miRNA
composition generates a breast cancer-specific signature.
The small RNA content of EVs is dominated by srRNAs that appear specifically secreted
from the cells. Most prominent among these are a series of srRNAs that map to the exact 5’end
compared to the expression in the parental cells. RPM, reads per million.C)Mapping of all small RNA fragments to
the 28S rRNA genomic region. Fragments compromising the first 22 nt of 28S rRNA is clearly present at a much
higher level than the corresponding transcript.D) The expression level of the 20 most abundant small RNAs in the
cell lines is compared to the expression in corresponding EVs.
doi:10.1371/journal.pone.0161824.g003
Table 1. Number of unique non-miRNA small RNAs andmiRNAs (tags) detected in the nine breast cancer EVs.
DU4475 HCC1569 Hs578T AU565 MCF7 MDA-MB-
231
MA-11 HCC1428 HCC1187 Average STD
Non-miRNA small
RNA,EV
1602
(59%)
1702
(61%)
1909
(63%)
1073
(53%)
1083
(61%)
2315 (66%) 2821
(78%)
2505
(86%)
2732
(81%)
1971
(68%)
662,6
(11%)
miRNA,EV 1113
(41%)
1106
(39%)
1135
(37%)
938
(47%)
679
(39%)
1182 (34%) 780
(22%)
399 (14%) 656 (19%) 888 (32%) 273,0
(11%)
doi:10.1371/journal.pone.0161824.t001
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Fig 4. Scatterplot analysis showing the correlation between the small RNA expression pattern in nine
breast cancer cell lines and the corresponding EVs isolated from cell culture media. Small RNA expression
is given in log2 reads per million (RPM), with the cellular expression shown on the x-axis and the EVs on the y-axis.
MiRNAs are plotted in red, while non-miRNA small RNAs are plotted in black. Pearson’s correlation is calculated
for the total small RNA expression.
doi:10.1371/journal.pone.0161824.g004
Table 2. Number of unique non-miRNA small RNAs andmiRNAs (tags) detected in the nine breast cancer cell lines.
DU4475 HCC1569 Hs578T AU565 MCF7 MDA-MB-
231
MA-11 HCC1428 HCC1187 Average STD
Non-miRNA small
RNA, cell line
1587
(56%)
1066
(49%)
1823
(59%)
1609
(60%)
1741
(58%)
1654 (57%) 1129
(51%)
1082
(50%)
1540
(57%)
1470
(55%)
295,8
(4%)
miRNA, cell line 1261
(44%)
1095
(51%)
1274
(41%)
1090
(40%)
1278
(42%)
1227 (43%) 1088
(49%)
1067
(50%)
1171
(43%)
1172
(45%)
89,0
(4%)
doi:10.1371/journal.pone.0161824.t002
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of the 28S rRNA, but which display size variations in their 3’ ends. In small RNA profiling
studies, srRNAs have often been ignored as unspecific degradation artifacts that have been gen-
erated during for instance library preparations [49]. However, the uniform nature of the 5’ 28S
rRNA fragments suggests that they are generated by precise processing of the rRNA rather
than by random degradation. In line with this, a similar srRNA has been shown to associate
with Ago in human fibroblasts [67]. Even though the presence of srRNAs in EVs has been
reported previously [10,68], this is the first report on the specific presence of this fragment in
Fig 5. Breast cancer EVs have a different composition of small RNAs than non-breast cancer EVs. A)
Hierarchical clustering of breast cancer EVs and non-breast cancer EVs on basis of the expression of 6569 unique
small RNAs. B) Transcriptome subtype distribution of small RNA sequences from five non-breast cancer EVs.C)
RNA28S5 small RNA expression in EVs from the breast cancer cells, breast cancer cells, and EVs from non-breast
cancer cells.D) Hierarchical clustering of breast cancer EVs and non-breast cancer EVs on basis of the expression
of 1087 miRNAs. E) Significantly differentially expressed small RNAs in breast cancer EVs as compared to non-
breast cancer EVs.
doi:10.1371/journal.pone.0161824.g005
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cancer cell derived EVs. Interestingly, as high levels of the fragment was detected intracellularly
in liver cells from healthy, normal mice, and that the fragment was almost completely absent in
liver cells from diabetic mice [67], it is tempting to speculate that the absence could be due to
specific secretion of the srRNA in the pathological condition and that this secretion has a role
in the progression of the disease. This points towards a potential function of the 5’ 28S srRNAs
in physiological and pathological processes. In our study, we detect the 5’ 28S rRNA fragments
in EVs from all cancer cell lines analyzed. Whether this srRNA is specific for all EVs, or solely
the EVs that derive from cancer cell lines, is not known, but deep sequencing analyses on exo-
somes derived from endothelial and immune cells failed to detect the fragment [10,69].
Switching our focus to the miRNAs, we find that miRNAs in EVs released by a particular
cell line, largely reflect the miRNA expression pattern within the cells. However, for three of
the cell lines very low amount of miRNAs was detected in the EVs even though the overall
intracellular level of miRNAs was equal to the other cell lines. This indicates that these cell
lines retain their cellular miRNAs. The molecular basis for this phenomenon is unclear, but
they may lack key protein components that are required for the incorporation of miRNAs into
vesicles that are destined for secretion. Even though our results show that the intracellular miR-
NAs are largely reflected in the EVs, we find specific miRNAs that are not equally distributed.
Previous studies have indeed shown that miRNAs are not randomly incorporated into exo-
somes [51,70,71], and moreover, some reports have shown that exosomal miRNA expression
levels are altered under different physiological conditions [34,35,72]. Here, we show that even
though all breast cancer cell lines express high levels of miR-21 variants, they are not secreted
in EVs. Cellular retention might thus be important for the cancerous phenotype. Increased
expression of miR-21 has for a long time been associated with advanced clinical stage, lymph-
node invasion, and shorter survival in breast cancer [73,74,75]. However, attempts to detect
circulating miR-21 in sera from breast cancer patients have so far given inconclusive results
[76,77,78,79,80,81]. Our observation that the general high expression of different miR-21 vari-
ants is not reflected in the secreted EVs, may provide an explanation for this inconsistency;
miR-21 could be actively retained in breast tumors similar to the situation in breast cancer cell
lines. Our data support the notion that the sorting of miRNAs into extracellular vesicles is spe-
cific and that certain miRNAs are actively retained in the cells. In line with this, a recent analy-
sis of the miRNA profiles of EVs secreted fromMCF7 and MCF10A cells confirmed different
distributions of miRNA in the cell and EV profiles, including a high level of miR-21 in the cells
compared to the EVs [82].
Finally, we find that the miRNA content in EVs derived from eight out of nine breast cancer
cell lines generate a specific signature that make them distinct from EVs secreted by other can-
cer cell lines. This is an important observation that indicates that profiling of miRNAs in EVs
isolated from an individual, can contribute in the diagnosis of breast cancer. Taken together,
our data argue strongly that small RNA sequences are specifically produced and packaged into
EVs. Recently, two papers have demonstrated that tumor-derived exosomes play key roles in
the generation of pre-metastatic niches in specific organs [18,19]. Here, specific integrin mole-
cules act as address tags for organotropic metastases [19]. In future studies, it will be interesting
to evaluate if specific small RNAs associate with unique exosomes that are destined for specific
metastatic niches.
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